MX2022014553A - Composicion farmaceutica para tratar enfermedad de higado graso. - Google Patents

Composicion farmaceutica para tratar enfermedad de higado graso.

Info

Publication number
MX2022014553A
MX2022014553A MX2022014553A MX2022014553A MX2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A
Authority
MX
Mexico
Prior art keywords
sup
sub
fatty liver
liver diseases
formula
Prior art date
Application number
MX2022014553A
Other languages
English (en)
Inventor
Naoki Ohyabu
Hideo Yukioka
Atsuyuki Shimazaki
Tadateru Hamada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2022014553A publication Critical patent/MX2022014553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una composición farmacéutica para tratar y/o prevenir la enfermedad de hígado graso, particularmente la enfermedad de hígado graso no alcohólica, la composición farmacéutica que tiene una excelente acción inhibidora selectiva de ACC2 y que no tiene efectos secundarios tales como un incremento en triglicéridos en plasma o una disminución en la concentración de plaquetas. Una composición farmacéutica para tratar y/o prevenir la enfermedad de hígado graso, la composición farmacéutica comprende un compuesto representado por la Fórmula (I): (ver Fórmula) (I) en donde R1 es haloalquilo o carbociclilo no aromático, R2 es un átomo de hidrógeno o halógeno, R3 es halógeno, el anillo A es un grupo representado por la fórmula: (ver Fórmula), -L1- es -O-(CH2)-, -(CH2)2-, o similares R4 es alquilo o haloalquilo, y R5 es alquilcarbonilo o carbamoilo, o una sal farmacéuticamente aceptable del mismo.
MX2022014553A 2020-05-21 2021-05-20 Composicion farmaceutica para tratar enfermedad de higado graso. MX2022014553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020089196 2020-05-21
JP2020134338 2020-08-07
PCT/JP2021/019088 WO2021235508A1 (ja) 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬

Publications (1)

Publication Number Publication Date
MX2022014553A true MX2022014553A (es) 2022-12-15

Family

ID=78707930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014553A MX2022014553A (es) 2020-05-21 2021-05-20 Composicion farmaceutica para tratar enfermedad de higado graso.

Country Status (10)

Country Link
US (1) US20230210822A1 (es)
EP (1) EP4154880A1 (es)
JP (1) JPWO2021235508A1 (es)
KR (1) KR20230013126A (es)
CN (1) CN115666558A (es)
AU (1) AU2021275292A1 (es)
CA (1) CA3182134A1 (es)
MX (1) MX2022014553A (es)
TW (1) TW202207919A (es)
WO (1) WO2021235508A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023090411A1 (ja) * 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356276A4 (en) * 2000-12-26 2005-02-02 Res Dev Foundation ACETYL-COENZYME A CARBOXYLASE 2 AS A TARGET IN THE REGULATION OF BULK FAT, FAT STORAGE, ENERGY HOMEOSTASY AND INSULIN ACTION
DK2499139T3 (da) 2009-11-10 2014-01-27 Pfizer N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere
HUE025078T2 (en) * 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
JP6114297B2 (ja) 2011-11-11 2017-04-12 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
JP6205152B2 (ja) 2013-03-25 2017-09-27 サイプレス セミコンダクター コーポレーション シリアル通信システム、受信装置およびシリアル通信方法
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
US11541046B2 (en) * 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds

Also Published As

Publication number Publication date
TW202207919A (zh) 2022-03-01
EP4154880A1 (en) 2023-03-29
JPWO2021235508A1 (es) 2021-11-25
WO2021235508A1 (ja) 2021-11-25
CN115666558A (zh) 2023-01-31
AU2021275292A1 (en) 2022-12-15
US20230210822A1 (en) 2023-07-06
KR20230013126A (ko) 2023-01-26
CA3182134A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
DOP2004001052A (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
MA32231B1 (fr) Composés organiques
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA200700103A1 (ru) НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
NO20073550L (no) Hydantoinderivater nyttige som metallproteinaseinhibitorer
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
PT828728E (pt) Di-hidrobenzofuranos de fenilo
MA31594B1 (fr) Composes organiques
SE0301232D0 (sv) Novel use
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
EA200401519A1 (ru) N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b
MX2022014553A (es) Composicion farmaceutica para tratar enfermedad de higado graso.
MA31901B1 (fr) Nouveaux derives diazeniumdiolates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA87822C2 (ru) Производные нафтилена как ингибиторы цитохрома p450
RU2008129623A (ru) Ингибиторы ccr9 активности
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth